Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

Met Non Small Cell Cancer Registry (MOMENT)

Sponsor: EMD Serono Research & Development Institute, Inc.

NCT ID: NCT05376891

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Not specified by the sponsor
How long the study runs
Study runs about 66 months (dates as stated)
About the drug or intervention
Not specified by the sponsor
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
Not specified
Who
All
Number of participants
700
Started
2022-10-04
Last checked
2026-09

Plain English Summary

What is this study?

  • • Testing a new treatment for cancer
  • • Clinical study - 700 participants
  • • The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time

Who can take part?

  • • Adults
  • • Diagnosed with cancer

Where?

  • • Torquay - Torbay Hospital
  • • Huddersfield - Huddersfield Royal Infirmary
  • • Bedford - Bedford General Hospital
  • • Birmingham - Birmingham Heartlands Hospital
  • • +11 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

More detail

This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

Cancer

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: Not specified
  • Who can join: All genders

What the study is looking for

  • ✓Participants who signed ICF
  • ✓Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations...
  • ✓Participants who are starting or are already being treated with treatment that goes through your whole body

Who cannot take part

  • ✗Participants who are enrolled in a clinical trial
See the full criteria
Inclusion Criteria: * Participants who signed ICF * Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay) * Participants who are starting or are already being treated with systemic therapy Exclusion Criteria: * Participants who are enrolled in a clinical trial

Where Is This Study? (15 UK sites)

Torbay Hospital

Torquay TQ2 7AA, United Kingdom

Recruiting
Site contact (verified)
Louise MedleyPrincipal Investigator

Huddersfield Royal Infirmary

Huddersfield HD3 3EA, United Kingdom

NOT_YET_RECRUITING
Site contact (verified)
Milly FinchPrincipal Investigator

Bedford General Hospital

Bedford, United Kingdom

Recruiting
Site contact (verified)
Venkata BulusuPrincipal Investigator

Birmingham Heartlands Hospital

Birmingham, United Kingdom

TERMINATED
Hospital R&D contact (matched)

Sarah Pountain Head of Research Governance

R&D@uhb.nhs.uk0121 371 4185

Royal Bournemouth Hospital

Bournemouth, United Kingdom

Recruiting
Site contact (verified)
Tom GeldartPrincipal Investigator

Velindre Cancer Centre

Cardiff CF14 2TL, United Kingdom

Recruiting
Site contact (verified)
Najmus IqbalPrincipal Investigator

The Royal Marsden Hospital

Chelsea, United Kingdom

Recruiting
Site contact (verified)
Sanjay PopatPrincipal Investigator

Northwick Park Hospital

Harrow, United Kingdom

Recruiting
Site contact (verified)
Arshi DentonPrincipal Investigator

Clatterbridge Cancer Centre - Liverpool

Liverpool, United Kingdom

Recruiting
Site contact (verified)
Carles EscriuPrincipal Investigator

Guy's Cancer Centre

London SE1 9RT, United Kingdom

NOT_YET_RECRUITING
Site contact (verified)
Daniel HughesPrincipal Investigator

Queen Elizabeth Hospital,Woolwich

London SE18 4QH, United Kingdom

Recruiting
Site contact (verified)
Daniel HugesPrincipal Investigator

St. George's Hospital

London SW17 0QT, United Kingdom

Recruiting
Site contact (verified)
Doriad AlrifaiPrincipal Investigator

Charing Cross Hospital

London, United Kingdom

Recruiting
Site contact (verified)
Joanne EvansPrincipal Investigator

Preston Hospital

Preston, United Kingdom

Recruiting
Site contact (verified)
Pavel BezecnyPrincipal Investigator

Great Western Hospital

Swindon SN3 6BB, United Kingdom

Recruiting
Site contact (verified)
Omar KhanPrincipal Investigator

How to Get in Touch

US Medical Information

Sponsor contact

CONTACT

888-275-7376 eMediUSA@emdserono.com

Communication Center

Sponsor contact

CONTACT

+49 6151 72 5200 service@emdgroup.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-09